Do drug transporter genomic variants and inhibitors protect against doxorubicin-induced cardiotoxicity in human induced pluripotent stem cell models?
Human induced pluripotent stem cell models can successfully identify genomic variants and inhibitors to protect against doxorubicin-induced cardiotoxicity, providing foundational data for future clinical trials.
This work demonstrates the power of the human induced pluripotent stem cell model to take a single nucleotide polymorphism from a statistical association through to drug discovery, providing human cell-tested data for clinical trials to attenuate DIC.
Magdy et al. (Tue,) studied this question.